aTyr Pharma, Inc.(US:ATYR) Globenewswireยท2025-09-16 18:03Core Insights - aTyr Pharma, Inc. announced topline results from its Phase 3 EFZO-FIT study, which did not meet its primary endpoint regarding the change in mean daily oral corticosteroid dose at week 48 [1] - Following the announcement, aTyr's stock price experienced a decline [1] Company Overview - aTyr Pharma, Inc. is a publicly traded company listed on NASDAQ under the ticker ATYR [1] - The company is currently under investigation by Holzer & Holzer, LLC to determine compliance with federal securities laws [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of representing shareholders and investors in class action and derivative litigation [3] - The firm has been recognized as an ISS top-rated securities litigation law firm for the years 2021, 2022, and 2023 [3]